Astellas appoints VP, global medicine safety
This article was originally published in Scrip
Astellas Pharma Global Development – a subsidiary of Astellas Pharma Inc, based in Tokyo, Japan – has appointed Robin J McGarry vice-president, global medicine safety head. For the past 13 years Ms McGarry worked as an independent consultant, providing pharmacovigilance, clinical, and regulatory strategic consulting services. And in the past she was vice-president of worldwide safety at Pfizer. Furthermore, Astellas Pharma Global Development has promoted Mark Weinberg to vice-president of Global Clinical Science at the company. Mr Weinberg joined Astellas in 2011 as global therapeutic area head in CNS and pain.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.